Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Content 2 Healthcare Names That Could Get a Big Boost From EarningsAuthored by Nathan Reiff. Posted: 1/20/2026. 
Key Points - An acceleration from last quarter's 4% year-over-year growth in nutrition segment sales could help boost Abbott Laboratories' revenue performance.
- Intuitive Surgical's preliminary fourth-quarter earnings results led to a modest dip in share price, perhaps due to middling forecasted da Vinci procedure growth for 2026.
- Still, overall adoption and revenue growth rates remain high, and the temporary decline may be an opportunity for long-term investors.
Active traders expect companies in the healthcare sector to see sizable share-price moves tied to milestones in the development of new therapies and medical products. Volatility in parts of the sector makes it a high-risk, high-reward opportunity. Another potential catalyst for meaningful price movement is healthcare earnings reports. The two companies below could be poised for immediate or longer-term gains depending on the signals their late-January earnings releases send. Analysts Expect Abbott to Overcome Nutrition Sluggishness A $211 billion healthcare giant that provides diagnostic tools, medical devices, pharmaceuticals and more, Abbott Laboratories (NYSE: ABT) is well known for continuous glucose monitoring (CGM), cardiac and vascular products. Jerome Powell says gold is not money. The Fed says inflation is under control and the dollar is strong. But look at what they do. Central banks bought more gold last year than any time since 1967. China dumped $100 billion in U.S. debt, then bought gold. Poland, Hungary, Singapore, and Turkey are all loading up. In 2022, the U.S. froze Russia's money and showed the world that assets can be seized. Now major nations want out. There's only one asset no one can freeze: gold. Get the name and ticker of one stock positioned for this shift. Despite some ups and downs, Abbott's share price is essentially flat over the last 12 months, with a 4.3% return that has underperformed the S&P 500. In the third quarter of 2025, Abbott met analyst expectations with earnings per share (EPS) of $1.30 but missed revenue estimates by more than $31 million, even though sales rose roughly 7% year over year (YOY). Weakness in the nutrition segment — which saw only a 4% YOY sales increase — held back stronger overall revenue performance. Another headwind was diagnostic sales in China, which have been pressured by tariffs and other trade issues. Still, the somewhat lackluster top- and bottom-line results may mask strengths elsewhere, including a 17% YOY increase in CGM product sales to $2 billion. Investors will be watching whether new higher-protein, lower-sugar formulations of Ensure and Glucerna can reignite growth in the nutrition category. Those launches could boost the segment and help accelerate overall sales. Given Abbott's earlier struggles with volume-based procurement that hurt diagnostics sales in China, it may be difficult for the company to fully reverse those trends. That could matter less if Abbott continues to perform well in medical devices, pharmaceuticals and core lab diagnostics outside China. Wall Street appears optimistic ahead of Abbott's end-of-year earnings: analysts at Barclays, Evercore ISI and others have reiterated Buy ratings or raised price targets in recent weeks. Overall, analysts see meaningful upside, with 19 rating ABT a Buy and four rating it a Hold — implying roughly 21% upside to the consensus target price. Intuitive's Preliminary Earnings Dip Could Be a Hidden Opportunity Intuitive Surgical (NASDAQ: ISRG) is similar in scale to Abbott but focuses narrowly on robot-assisted surgical systems. Investors already have an idea of what to expect from the company's fourth-quarter report thanks to preliminary results issued on Jan. 14, 2026. Global procedures rose sharply, with total quarterly worldwide procedures up 18% YOY. Intuitive's da Vinci system continued to gain adoption, helping drive fourth-quarter revenue up 19% YOY to $2.87 billion. Yet the market responded to the preliminary results with a modest sell-off in ISRG shares. A likely contributor was relatively conservative guidance for 2026: Intuitive expects da Vinci procedures to grow 13%–15% next year, a slower pace than the 18% YOY gain in 2025. Longer term, Intuitive's prospects remain compelling — driven not only by demand for its surgical platforms but also by an often-overlooked pipeline that includes imaging agents and other therapeutics. If the company's official fourth-quarter results provide a fuller picture of strengths heading into the new year, shares could rebound from the earlier dip. Analysts remain largely bullish: 18 currently rate ISRG a Buy, with the remainder split between Holds and Sells, and consensus upside potential of more than 16%.
| 
0 Response to "We're excited to have you on board"
Post a Comment